Tech Launch Arizona commercializes inventions stemming from research, hosted its ninth annual I-Squared Awards and Expo event. Along with honoring the top inventors, entrepreneurs, and community leaders dedicated to commercializing UArizona inventions.

The College of Medicine – Tucson and Tech Launch Arizona recognized inventors for their dedication to creating impact from their innovative work at a special luncheon held on September 15, 2022.

Aqualung Therapeutics, an early-stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for unchecked inflammation has published another study touting the effectiveness of its anti-inflammatory ALT-100 monoclonal anti

The BIO5 Postdoctoral Fellowship grants financial support and facilitates mentorship to enrich awardees’ research aims and career development.

Aqualung Therapeutics, a Tucson-based drug startup headed by UArizona's Joe G. N. Garcia, has won a major investment to help take its flagship drug into initial human clinical trials for treatment of life-threatening lung inflammation.

Aqualung Therapeutics, an early-stage immunotherapeutics company with an anti-inflammatory therapeutic platform for life-threatening unchecked inflammation, has closed a $2.5M convertible note fundraise led by a $1.5M investment.

Aqualung Therapeutics Corp., an early stage immunotherapeutics company which has developed an anti-inflammatory therapeutic platform for life-threatening unchecked inflammation, will be presenting at the annual Biotech Showcase in San Francisco.

Aqualung Therapeutics receives NIH Fastrack award to continue developing therapeutic for patients with Acute Respiratory Distress Syndrome.

6/7/19-BIO5 eNews Determining patients that are susceptible to heparin-induced thrombocytopenia could prevent dangerous and possibly life threatening blood clotting

Dr. Yves Lussier, was one of multiple UA faculty members who attended the Precision Medicine Initiative Summit held in Washington D.C., of a nationwide Precision Medicine Initiative to pioneer a new model of patient-powered research.